Dangerous Synthetic Drug Control Act of 2016

Bill: 114-hr-3537
Sponsor: full_name: Rep. Dent, Charles W. [R-PA-15]
Introduced: 2015-09-17
Policy area: Crime and Law Enforcement
Subjects: Drug trafficking and controlled substances
Latest action: action_date: 2016-09-27
text: Received in the Senate and Read twice and referred to the Committee on the Judiciary.

Summaries:
action_date: 2015-09-17
action_desc: Introduced in House
text: <p><b>Synthetic Drug Control Act of 2015</b></p> <p>This bill amends the Controlled Substances Act (CSA) to modify the definition of &quot;controlled substance analogue&quot; to mean a substance that has a similar (previously, substantially similar) chemical structure and pharmacological effect to a schedule I controlled substance. </p> <p>The CSA's requirements, prohibitions, and restrictions with respect to schedule I controlled substances apply to the manufacture, importation, distribution, and sale (but not possession) of a controlled substance analogue.</p> <p>The bill amends the Controlled Substances Analogue Enforcement Act of 1986 to add certain synthetic substances to schedule I of the CSA. </p>

action_date: 2016-09-26
action_desc: Passed House amended
text: <p><b>Dangerous Synthetic Drug Control Act of 2016</b></p> <p>(Sec. 2) This bill amends the Controlled Substances Act to add certain synthetic opioids, hallucinogens, and cannabinoids to schedule I. (A schedule I controlled substance is a drug, substance, or chemical that: has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.)</p>

tv_txt: I 114th CONGRESS 1st Session H. R. 3537 IN THE HOUSE OF REPRESENTATIVES September 17, 2015 Mr. Dent (for himself, Mr. Himes , Mr. Meehan , Mr. Dold , Mr. Tiberi , Mr. Costello of Pennsylvania , Mr. Hanna , Mr. Thompson of Pennsylvania , Mr. Rogers of Kentucky , Mr. Murphy of Pennsylvania , Mr. Barletta , Ms. Norton , Mr. Lance , Mrs. Comstock , Mr. Katko , Ms. Ros-Lehtinen , and Mr. Jolly ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on the Judiciary , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend the Controlled Substances Act to clarify how controlled substance analogues are to be regulated, and for other purposes.

1. Short title This Act may be cited as the Synthetic Drug Control Act of 2015 . 2. Controlled substance analogues (a) Expansion of definition (1) In general Clauses (i), (ii), and (iii) of section 102(32)(A) of the Controlled Substances Act ( 21 U.S.C. 802(32)(A) ) are amended by striking substantially each place it appears. (2) Rule of construction Section 102(32)(A) of the Controlled Substances Act ( 21 U.S.C. 82(32)(A) ) shall not be construed to require that a substance satisfy more than one of the clauses listed in such section 102(32)(A) to meet the definition of a controlled substance analogue. (b) Limitation on treatment as controlled substances Section 203 of the Controlled Substances Act ( 21 U.S.C. 813 ) is amended by inserting before the period at the end the following: for purposes of prohibitions, restrictions, and other requirements with respect to manufacture, importation, distribution, and sale . 3. Treatment of certain designer drugs as schedule I controlled substances (a) In general Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ) is amended by adding at the end the following: (e) (1) Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a substances listed in paragraphs (2) through (10), or which contains the salts, isomers, and salts of isomers thereof whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation. (2) Phenylalkylamines The substances listed in this paragraph consist of the following phenylalkylamines: (A) 2–(ethylamino)–1–(4-methylphenyl)–1-propanone. (B) 1–(4-ethylphenyl)–2–(methylamino)–1-propanone. (C) 1–(3-fluorophenyl)–2–(methylamino)–1-propanone. (D) 1–(4-fluorophenyl)–2–(methylamino)–1-propanone. (E) 1–(4-methoxyphenyl)–2–(methylamino)–1-propanone. (F) 2–(ethylamino)–1–(4-methoxyphenyl)–1-propanone. (G) 1–(2-naphthalenyl)–2–(1-pyrrolidinyl)–1-pentanone. (H) 1–(1,3-benzodioxol-5-yl)–2–(ethylamino)–1-propanone. (I) 1–(1,3-benzodioxol-5-yl)–2–(methylamino)–1-butanone. (J) 1–(1,3-benzodioxol-5-yl)–2–(methylamino)–1-pentanone. (K) 2–(ethylamino)–1-phenyl-1-propanone. (L) 1-phenyl-2–(1-pyrrolidinyl)–1-propanone. (M) 1–(4-methylphenyl)–2–(1-pyrrolidinyl)–1-propanone. (N) 1–(4-methoxyphenyl)–2–(1-pyrrolidinyl)–1-propanone. (O) 1–(1,3-benzodioxol-5-yl)–2–(1-pyrrolidinyl)–1-propanone. (P) 1-phenyl-2–(1-pyrrolidinyl)–1-pentanone. (Q) 2-amino-1–(4-fluoro)–1-propanone. (R) 2–(methylamino)–1-phenyl-1-pentanone. (S) 2–(ethylamino)–1–(4-ethylphenyl)–1-propanone. (T) 2–(dimethylamino)–1-phenyl-1-propanone. (U) 1–(1,3-benzodioxol-5-yl)–2–(1-pyrrolidinyl)–1-butanone. (V) 1–(methylphenyl)–2–(1-pyrrolidinyl)–1-hexanone. (W) 2–(methylamino)–1-phenyl-1-butanone. (X) 2–(methylamino)–1-p-tolyl-1-butanone. (Y) 1–(4-methylphenyl)–2–(1-pyrrolidinyl)–1-butanone. (Z) 1–(3,4-dimethylphenyl)–2–(methylamino)–1-propanone. (AA) 1-phenyl-2–(1-pyrrolidinyl)–1-butanone. (BB) 1–(1,3-benzodioxol-5-yl)–2–(dimethylamino)–1-propanone. (CC) 1–(4-methylphenyl)–2–(benzylamino)–1-propanone. (DD) 1–(1-naphthy)–2–(1-pyrrolidinyl)–1-pentanone. (EE) 1–(1,3-benzodioxol-5-yl)–2–(benzylamino)–1-propanone. (FF) 1–(1,3-benzodioxol-5-yl)–2–(benzylamino)–1-butanone. (GG) 1–(1,3-benzodioxol)–2-[hydroxy(methyl)-amino]-1-propanone. (HH) 1–(1,3-benzodioxol-5-yl)–2–(dimethylamino)–1-butanone. (II) 2–(ethyl(methyl)amino)–1-phenyl-butanone. (JJ) 1–(4-bromophenyl)–2–(methylamino)–1-propanone. (KK) 2–(ethyl(methyl)amino-1-phenyl-1-propanone. (LL) 2–(methylamino)–1-m-tolyl-1-propanone. (MM) 2–(pyrrolidin-1-yl)–1–(thiophen-2-yl)–1-pentanone. (NN) 1–(4-fluorophenyl)–2–(methylamino)–1-butanone. (OO) 1–(4-methoxyphenyl)–2–(pyrrolidin-1-yl)–1-butanone. (PP) 1–(4-ethylphenyl)–2–(pyrrolidin-1-yl)–1-butanone. (QQ) 1–(4-methoxy-3-methylphenyl)–2–(methylamino)–1-propanone. (RR) 2–(ethylamino)–1–(3-methylphenyl)–1-propanone. (SS) 2-amino-(1H-indol-5-yl)propan-1-one. (TT) 1-phenyl-2–(piperidin-1-yl)butan-1-one. (UU) 2-methylamino-1–(2,4,5-trimethylphenyl)-propan-1-one). (VV) 1-phenyl-2–(pyrrolidin-1-yl)heptan-1-one. (WW) 1-phenyl-2–(pyrrolidin-1-yl)hexan-1-one. (XX) 1–(4-fluorophenyl)–2–(pyrrolidin-1-yl)pentan-1-one. (YY) 1–(benzo[d][1,3]dioxol-5-yl)–2–(dimethylamino)pentan-1-one. (ZZ) 1–(2-fluorophenyl)–N-methyl-propan-2-amine. (AAA) 1–(2-fluorophenyl)-propan-2-amine. (BBB) 1–(3-fluorophenyl)- propan-2-amine. (CCC) 1–(3-fluorophenyl)–N-methyl-propan-2-amine. (DDD) 1–(4-fluorophenyl)- propan-2-amine. (EEE) 1–(4-fluorophenyl)–N-methyl-propan-2-amine. (FFF) 1–(4-methylphenyl)propan-2-amine. (GGG) N-ethyl-N-methyl-1-phenylpropan-2-amine. (HHH) 1–(benzofuran-4-yl)propan-2-amine. (III) 1–(benzofuran-5-yl) propan-2-amine. (JJJ) 1–(2,3-dihydrobenzofuran-5-yl)proan-2-amine. (KKK) 1–(benzofuran-6-yl)- propan-2-amine. (LLL) 1–(2,3-dihydrobenzofuran-6-yl)proan-2-amine. (MMM) 1–(4-methoxyphenyl)–N-methyl-propan-2-amine. (NNN) N,N-dimethyl-1-phenylpropan-2-amine. (OOO) 1–(2,3-dihydro-1H-inden-5-yl)propan-2-amine. (PPP) 5,6,7,8-tetrahydrobenzo[1,3]-benzodioxol-7-amine. (QQQ) a -methyl-4–(methylthio)-benzene-ethanamine. (RRR) 1–(4-chlorophenyl)-propan-2-amine. (SSS) 1–(2,4,6-trimethoxyphenyl)-propan-2-amine. (TTT) 1–(2,4,5-trimethoxyphenyl)-propan-2-amine. (UUU) 1–(2,5-dimethylphenyl)-propan-2-amine. (VVV) 1–(3,4-dimethylphenyl)-propan-2-amine. (WWW) N–(1-phenylpropan-2-yl)propan-1-amine. (XXX) 4–(2-aminopropyl)phenol. (YYY) 3,4-methylenedioxy-N,N-dimethyl-amphetamine. (ZZZ) N-ethyl-1–(4-methoxyphenyl)propan-2-amine. (AAAA) 1–(benzofuran-5-yl)–N-methylpropan-2-amine. (BBBB) 6,7-dihydro-5H-inden[5,6-d][1,3]dioxol-6-amine. (CCCC) 5-iodo-2,3-dihydro-1H-inden-2-amine. (DDDD) 2,3-dihydro-1H-inden-2-amine. (EEEE) 5-methoxy-6-methyl-2,3-dihydro-1H-inden-2-amine. (FFFF) N-methyl-6,7-dihydro-5H-cyclopenta[1,3]-benzodioxol-6-amine. (GGGG) N-methyl-2,3-dihydro-1H-inden-2-amine. (HHHH) 2-[4–(2-fluoroethylthio)–2,5-dimethoxyphenyl]ethanamine. (IIII) 8-bromo-2,3,6,7-tetrahydro-benzo[1,2-b;4,5-b’]difuran-4-ethanamine. (JJJJ) 4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)-methyl-benzene-ethamine. (KKKK) 2–(4-chloro-2,5-dimethoxyphenyl)–N–(2-methoxybenzyl)-ethanamine. (LLLL) 2–(2,5-dimethoxy-3,4-dimethylphenyl)-ethanamine. (MMMM) 2–(4-methyl-2,5-dimethoxyphenyl)–N–(2-methoxybenzyl)-ethanamine. (NNNN) 2–(4-ethyl-2,5-dimethoxyphenyl)–N–(2-methoxybenzyl)-ethanamine. (OOOO) 2–(2,5-dimethoxy-3,4-dimethylphenyl)–N–(2-methoxybenzyl)-ethanamine. (PPPP) 2–(2,5-dimethoxyphenyl)–N–(2-methoxybenzyl)-ethanamine. (QQQQ) 2–(4-bromo-2,5-dimethoxyphenyl)–N–(2-methoxybenzyl)-ethanamine. (RRRR) 2–(2,5-dimethoxyphenyl-4-nitro)–N-[(2-methoxyphenyl)methyl]-ethanamine. (SSSS) 1–(4-iodo-2,5-dimethoxyphenyl)propan-2-amine. (TTTT) 1–(4-bromofuro[2,3-f]benzofuran-8-yl)propan-2-amine. (UUUU) 1–(4-chloro-2,5-dimethoxyphenyl)propan-2-amine. (VVVV) 1–(4-bromo-2,3,6,7-terahydrofuro[2,3-f]benzofuran-8-yl)propan-2-amine. (WWWW) (2,5-dimethoxyphenyl)-propan-2-amine. (XXXX) 1-[4–(ethylthio)–2,5-dimethoxyphenyl)propan-2-amine. (YYYY) 1–(4-ethoxy-2,5-dimethoxyphenyl)propan-2-amine. (ZZZZ) 1-[2,5-dimethoxy-4–(propylthio)phenyl]propan-2-amine. (AAAAA) 1–(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine. (BBBBB) N-benzyl-2-phenylethanamine. (CCCCC) N,N-dimethyl-2-phenylethanamine. (DDDDD) 6-chloro-aminotetralin. (EEEEE) 2-phenyl-propan-1-amine. (FFFFF) 2-phenethylamine. (GGGGG) 1-methylamino-1–(3,4-methylendioxy-phenyl)propane. (HHHHH) N-methyl-3-phenylbicyclo[2.2.1]heptan-2-amine. (IIIII) 1–(2-methoxyphenyl)–N-methylpropan-2-amine. (JJJJJ) 2–(4–(allyloxy)–3,5-dimethoxyphenyl)ethanamine. (KKKKK) 4-methylhexan-2-amine. (LLLLL) 4-methyl-5-phenyl-2-amino-oxazoline. (MMMMM) N-methyl-1-thiophen-2-yl)propan-2-amine. (NNNNN) (3-dimethylamino-2,2-dimethylpropyl)–4-aminobenzoate. (OOOOO) 1–(4-fluorophenyl)–2–(methylamino)-propan-1-ol. (PPPPP) 4-methyl-5-p-tolyl-4,5-dihydrooxazol-2-amine. (QQQQQ) 1-phenyl-2–(pyrrolidin-1-yl)propan-1-ol. (3) Cannabimimetic agents The substances listed in this paragraph consist of the following cannabimimetic agents: (A) (4-ethyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone. (B) 2–(2-methylphenyl)–1–(1-pentyl-1H-indol-3-yl)-ethanone. (C) 1-[1–(2-cyclohexylethyl)–1H-indol-3-yl]-2–(2-methoxyphenyl)-ethanone. (D) [1–(5-fluoropentyl)–1H-indol-3-yl](2-iodophenyl)methanone. (E) (2-methyl-1-[(1-methylpiperidin-2-yl)methyl]-6-nitro-1H-indol-3-yl)methanone. (F) (1-butyl-1H-indol-3-yl)(4-methoxyphenyl)-methanone. (G) (1-butyl-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone. (H) [1–(5-fluoropentyl)–1H-indol-3-yl](4-methyl-1-naphthalenyl)-methanone. (I) [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-1-naphthalenyl-methanone. (J) 3–(4-methoxyphenyl)–2-methyl-1-[(2–(4-morpholinyl)ethyl)–1H-indol-3-yl]-methanone. (K) [2,3-dihydro-5-methyl-3–(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl- methanone. (L) 2–(3-methoxyphenyl)–1–(1-pentyl-1H-indol-3-yl)-ethanone. (M) (2-iodophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-methanone. (N) [1-[(1-methyl-2-piperdinyl)methyl]-1H-indol-3-yl]tricycle[3.3.1.13,7]dec-1-yl-methanone. (O) 1-naphthalenyl(1-propyl-1H-indol-3-yl)-methanone. (P) 5-[3–(1-naphthoyl)–1H-indole-1-yl]pentanenitrile. (Q) 3–(1-naphthenylmethyl)–1-pentyl-1H-indole. (R) (2-methyl-1-propyl-1H-indol-3-yl)–1-napthalenyl-methanone. (S) 1-naphthalenyl[1–(4-penten-1-yl)–1H-indol-3-yl]-methanone. (T) (4-bromonaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone. (U) (4-fluoronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone. (V) (2-methyl-1-phenyl-1H-indol-3-yl)–1-naphthalenyl-methanone. (W) 2–(2-chlorophenyl)–1–(1-pentyl-1H-indol-3-yl)-ethanone. (X) [1–(5-chloropentyl)–1H-indol-3-yl](2-iodophenyl)-methanone. (Y) (adamantan-1-yl)(1-pentyl-1H-indol-3-yl)-methanone. (Z) (2-iodo-5-nitrophenyl)-[1–(1-methylpiperidin-2-ylmethyl)–1H-indol-3-yl]-methanone. (AA) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclo-propyl)methanone. (BB) [1–(5-fluoropentyl-1H-indol-3-yl)](2,2,3,3-tetramethylcyclo-propyl)methanone. (CC) [1–(2-morpholinoethyl)–1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone. (DD) 1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indol-3-yl-(2,2,3,3-tetramethylcyclopropyl)methanone. (EE) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide. (FF) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide. (GG) 1–(5-fluoropentyl)–N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide. (HH) [1–(5-chloropentyl)–1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone. (II) (1-isopentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone. (JJ) 1–(5-fluoropentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide. (KK) (1-pentyl-1H-indol-3-yl)(4-propyl-1-naphthalenyl)-methanone. (LL) [1–(5-chloropentyl)–1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone. (MM) (4-methyl-naphthalen-1-yl)[1–(pent-4-en-1-yl)–1H-indol-3-yl]methanone. (NN) (2-methoxy-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone. (OO) (3-methoxy-phenyl)(1-pentyl-1H-indol-3-yl)methanone. (PP) [1–(5-fluoropentyl)–1H-indol-3-yl](4-ethyl-1-naphthalenyl)-methanone. (QQ) quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate. (RR) quinolin-8-yl 1–(5-fluoropentyl-1H-indole-3-carboxylate. (SS) 1–(cyclohexylmethyl)–8-quinolinyl-ester-1H-indole-3-carboxylic acid. (TT) N–(1-amino-3-methyl-1-oxobutan-2-yl)–1-pentyl-1H-indazole-3-carboxamide. (UU) 1–(5-fluoropentyl)–N–(naphthalene-1-yl)–1H-indole-3-carboxamide. (VV) N–(1-amino-3-methyl-1-oxobutan-2-yl)–1–(4-fluorobenzyl)–1H-indazole-3-carboxamide. (WW) N–(1-amino-3,3-dimethyl-1-oxobutan-2-yl)–1–(4-fluorobenzyl)–1H-indazole-3-carboxamide. (XX) N–(1-amino-3,3-dimethyl-1-oxobutan-2-yl)–1-pentyl-1H-indole-3-carboxamide. (YY) 2-iodophenyl)(1-pentyl-1H-indol-3-yl)methanone. (ZZ) [5–(2-methylphenyl)–1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone. (AAA) 1-pentyl-N–(naphthalene-1-yl)–1H-indole-3-carboxamide. (BBB) 1–(5-chloropentyl)–1H-indol-3-yl](4-methyl-1-naphthalenyl)-methanone. (CCC) (4-methyl-naphthalen-1-yl)[2-methyl-1–(pent-4-en-1-yl)–1H-indol-3-yl)]methanone. (DDD) [1–(5-fluoropentyl)–1H-indol-3-yl](o-tolyl)methanone. (EEE) (2-ethylphenyl)(1–(5-fluoropentyl)–1H-indol-3-yl)methanone. (FFF) [1–(5-chloropentyl)–1H-indol-3-yl](naphthalen-1-yl)methanone. (GGG) [1–(5-bromopentyl)–1H-indol-3-yl](naphthalen-1-yl)methanone. (HHH) (1–(5-fluoropentyl)–1H-indazol-3-yl)(naphthalene-1-yl)methanone. (III) 1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone. (JJJ) (1–(1-methylazepan-2-yl)–1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone. (KKK) 4-hydroxy-3,3,4-trimethyl-1–(1-pentyl-1H-indol-3-yl)pentan-1-one. (LLL) [1–(4-fluoropentyl)–1H-indol-3-yl]-1-naphthenyl-methanone. (MMM) 2–(2-iodophenyl)–1–(1-pentyl-1H-indol-3-yl)ethanone. (NNN) (1-hexyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone. (OOO) (2,2,3,3-tetramethylcyclopropyl)[1–(4,4,4-trifluorobutyl)–1H-indol-3-yl]methanone. (PPP) 7-methoxy-1–(2-morpholinoethyl)–N–((1S,4R)–1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)–1H-indole-3-ca rboxamide. (QQQ) quinolin-8-yl 1–(4-fluorobenzyl)–1H-indole-3-carboxylate. (RRR) naphthalen-1-yl 1–(4-fluorobenzyl)–1H-indole-3-carboxylate. (SSS) N–(1-amino-3,3-dimethyl-1-oxobutan-2-yl)–1-pentyl-1H-indazole-3-carboxamide. (TTT) N–(1-amino-3,3-dimethyl-1-oxobutan-2-yl)–1–(5-fluoropentyl)–1H-indole-3-carboxamide. (UUU) (1–(4-fluoropentyl)–1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone. (VVV) 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)methanone. (WWW) N-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide. (XXX) N–(1-amino-3-methyl-1-oxobutan-2-yl)–1–(cyclohexyl methyl)–1H-indazole-3-carboxamide. (YYY) naphthalene-1-yl(9-pentyl-9H-carbazol-3-yl)methanone. (ZZZ) naphthalene-1-yl 1–(5-fluoropentyl)–1H-indole-3-carboxylate. (AAAA) methyl 3-methyl-2–(1-pentyl-1H-indazole-3-carboxamido. (BBBB) methyl 2–(1–5-fluoropentyl)–1H-indazole-3-caboxamido)–3-methylbutanoate. (CCCC) N-benzyl-1-pentyl-1H-indole-3-carboxamide. (DDDD) N-benzyl-1–(5-fluoropentyl)–1H-indole-3-carboxamide. (EEEE) methyl 2–(1–(4-fluorobenzyl)–1H-indazole-3-carboxamido)–3-methylbutanoate. (FFFF) quinolin-8-yl 1-pentyl-1H-indazole-3-carboxylate. (GGGG) quinolin-8-yl 1–(5-fluoropentyl)–1H-indazole-3-carboxylate. (HHHH) naphthalene-2-yl 1–(2-fluorophenyl)–1H-indazole-3-carboxylate. (IIII) N–(1-amino-3,3-dimethyl-1-oxobutan-2-yl)–1–(cyclohexylmethyl)–1H-indazole-3-carboxamide. (JJJJ) (1–(4-flourobenzyl)–1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone. (KKKK) N–(1-amino-1-oxo—3-phenylpropan-2-yl)–1–(5-fluoropentyl)–1H-indole-3-carboxamide. (LLLL) N–(1-amino-1-oxo—3-phenylpropan-2-yl)–1–(5-fluoropentyl)–1H-indazole-3-carboxamide. (MMMM) methyl (1–(cyclohexylmethyl)–1H-indazole-3-carbonyl-L-valinate. (NNNN) N-[(1–(cyclohexylmethyl)–1H-indazole-3yl)carbonyl]-3-methyl-L-valine, methyl ester. (OOOO) methyl 2–(1–(cyclohexylmethyl)–1H-indole-3-carboxamido)–3,3-dimethylbutanoate. (PPPP) (1–(5-fluoropentyl)–1H-benzo[d]imidazole-2-yl)(naphthalene-1-yl)methanone. (QQQQ) (1–(4-fluorobenzyl)–1H-indol-3-yl)(napthalen-1-yl)methanone. (RRRR) methyl 2–(1–(4-fluorobenzyl)–1H-indazole-3-carboxamido)–3,3-dimethylbutanoate. (SSSS) quinolin-8-yl 1–(4-fluorobenzyl)–1H-indazole-3-carboxylate. (TTTT) N–(adamantan-1-yl)–1–(4-fluorobenzyl)–1H-indazole-3-carboxamide. (UUUU) N–(1-amino-3-methyl-1-oxobutan-2-yl)–1–(5-fluoropentyl)–1H-indole-3-carboxamide. (VVVV) 2-[(1S,3R)–3-hydroxycyclohexyl]-5–(2-methylheptyl-2-yl)phenol. (WWWW) 2-[(1S,3R)–3-hydroxycyclohexyl]-5–(2-methyldodecanyl-2-yl)phenol. (XXXX) 3-hydroxy-2[3-methyl-6–(1-methylethyenyl)–2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione. (YYYY) 4-[4–(1,1-dimethylheptyl)–2,6-dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2-ene-2-methanol. (ZZZZ) 1-naphthalenyl[4–(pentylox)–1-naphthalenyl]-methanone. (AAAAA) 3–(2–(hydroxymethyl)–2,3-dihydro-1H-inden-4-yloxy)phenyl 4,4,4-trifluorobutane-1-sulfonate. (BBBBB) N–(benzo[1,3]dioxol-5-ylmethyl)–7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide. (CCCCC) N-[3–(2-methoxyethyl)–4,5-dimethylthiazol-2-ylidene]-2,2,3,3-tetramethylcyclopropane-carboxamide. (DDDDD) 5-chloro-3-ethyl-N-[4–(piperidin-1-yl)phenethyl)–1H-indole-2-carboximide. (EEEEE) N-[4–(dimethylamino)phenethyl]-3-ethyl-5-fluoro-1H-indole-2-carboximide. (FFFFF) N–(1-benzylpyrrolidin-3-yl)–5-chloro-3-ethyl-1H-indole-2-carboxamide. (GGGGG) [5–(2-fluorophenyl)–1-pentyl-1H-pyrrol-3-yl](naphthalene-1-yl)methanone. (HHHHH) (3’-(aminocarbonyl)[1,1’-biphenyl]-3-yl)-cyclohexyl-carbamate. (IIIII) 5–(biphenyl-4-ylmethyl)–N,N-dimethyl-1H-tetrazole-1-carboxamide. (JJJJJ) 6-methyl-2–(p-tolylamino)–4H-benzo[d][1,3]oxazin-4-one. (KKKKK) [1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester. (LLLLL) 4-hydroxy-N–(4-hydroxyphenethyl)–3–(pentylamino)-benzamide. (MMMMM) 3’-carbamoyl-6-hydroxy-[1,1’-biphenyl]-3-yl cyclohexylcarbamate. (4) Arylcyclohexamines The substances listed in this paragraph consist of the following arylcyclohexamines: (A) 1–(3-methoxyphenyl)–N-propylcyclohexan-amine. (B) 2–(ethylamino)–2–(3-methoxyphenyl)cyclohexanone. (C) 1-phenylcyclohexan-amine. (D) 1-[1–(benzothiophen-2-yl)cyclohexyl]piperidine. (E) 1–(1-p-tolylcyclohexyl)-piperidine. (F) 1–(4-methoxyphenyl)–N-propylcyclohexan-amine. (G) 1-[1–(4-methoxyphenyl)cyclohexyl]-piperidine. (H) 1-[1–(3-methoxyphenyl)cyclohexyl]-piperidine. (I) 1-phenyl-N-propylcyclohexanamine. (J) N–(2-methoxyethyl)–1-phenylcyclohexan-amine. (K) N–(2-ethoxyethyl)–1-phenylcyclohexan-amine. (L) N–(3-methoxypropyl)–1-phenylcyclohexan-amine. (M) 3-[1–(piperidin-1-yl)cyclohexyl]-phenol. (N) 2–(methoxyphenyl)–2–(methylamino)cyclohexanone. (O) N-ethyl-1–(thiophen-2-yl)cyclohexanamine. (P) (2–(2-chlorophenyl)–2–(ethylamino)-cyclohexanone). (5) Tryptamines The substances listed in this paragraph consist of the following tryptamines: (A) 2–(1H-indol-3-yl)–N-methyl-ethanamine. (B) N–(2–(1H-indol-3-yl)ethyl-N-methylpropan-2-amine. (C) N-[2–(1H-indol-3-yl)ethyl]-N-isopropylpropan-2-amine. (D) N,N-dipropyl-1H-indole-3-ethanamine. (E) 3-[2–(diethylamino)ethyl]-1H–4yl acetate. (F) 3–(2-[isopropyl(methyl)amino]ethyl)–1H-indol-4-ol. (G) 3-[2–(bis[1-methylethyl]amino)ethyl]-1H-indol-4-ol acetate. (H) 3–(2-[isopropyl(methyl)amino]ethyl)–1H-indol-4-ol acetate. (I) 3-[2–(dimethylamino)ethyl]-1H-indol-4-yl acetate. (J) 4-hydroxy-N,N-diethyl-1H-indole-ethanamine. (K) 4-methoxy-N,N-dimethyl-1H-indole-3-ethanamine. (L) 3–(2–(diisopropylamino)ethyl)–1H-indol-4-ol. (M) 3-[2–(ethyl[methyl]amino)ethyl]-1H-indol-4-ol. (N) 3-[2–(ethyl[methyl]amino)ethyl]-1H-indol-4-yl acetate. (O) 3–(2–(dipropylamino)ethyl)–1H-indol-4-ol. (P) 3-[2–(dipropylamino)ethyl]-1H-indol-4-yl acetate. (Q) 4-acetoxy-N,N-di-2-propen-1-yl-1H-indole-3-ethanamine. (R) 5-methoxy-N,N-di-2-propen-1-yl-1H-indole-3-ethanamine. (S) 3–(2–(dimethylaminoethyl)–1H-indol-5-ol. (T) 2–(5-methoxy-1H-indol-3-yl)–N,N-dimethylethanamine. (U) N-[2–(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropyl. (V) 1–(5-methoxy-1H-indol-3-yl)propan-2-amine. (W) 3-[2–(dimethylamino)-ethyl]-1H-indol-5-yl acetate. (X) N-[2–(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine. (Y) N,N-diethyl-2–(5-methoxy-1H-indol-3-yl)ethanamine. (Z) N-ethyl-2–(5-methoxy-1H-indol-3-yl)–N-methyl-ethanamine. (6) Benzylpiperidines The substances listed in this paragraph consist of the following benzylpiperidines: (A) 2–(diphenylmethyl)-piperidine. (B) 2-benzhydrylpyrrolidine. (C) a , a -diphenyl-(pyrrolidin-2-yl)methanol. (D) methyl 2–(3,4-dichlorophenyl)–2–(piperdin-2-yl)acetate. (E) methyl 2–(3-chlorophenyl)–2–(piperidin-2-yl)acetate. (F) methyl 2–(piperidin-2-yl)–2-p-tolylacetate. (G) methyl 2–(4-fluorophenyl)–2–(piperidin-2-yl)acetate. (H) ethyl 2-phenyl-2–(piperidin-2-yl)acetate. (7) Benzodiazepines The substances listed in this paragraph consist of the following benzodiazepines: (A) 4–(2-chlorophenyl)–2-ethyl-9-methyl-6H-thieno-[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine. (B) 7-bromo-5–(2-chlorophenyl)–1H-benzo[e][1,4]diazepin-2(3H)-one. (C) 8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3a][1,4]benzodiazepine. (D) 3-methyl-6-[3–(trifluoromethyl)phenyl][1,2,4]triazol[4,3-b]pyridazine. (E) 6–(5-chloro-2-pyridyl)–6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate. (8) Opioids and opioid-like substances The substances listed in this paragraph consist of the following opioids and opioid-like substances: (A) 2–(1,3-dimethoxybuta-1,3-dien-2-yl)–3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quin olizine. (B) (2a,4aR,6aR,7R,9S,10aS10bR)-methyl-9-acetoxy-2–(furan-3-yl)–6a,10b-dimethyl-4,10-dioxododecahydro-1 H-benzo[f]isochromene-7-carboxylate. (C) 3,4-dichloro-N–([1–(dimethylamino)cyclohexyl]methyl)benzamide. (D) 3-[2–(amino-1-methylethyl)–1-hydroxycyclohexyl]-phenol. (E) 4,5-epoxy-17-methylmorphinan-3-ol. (F) N-phenyl-N-[1–(2-phenethyl)–4-piperidinyl] acetamide. (G) N–(1-benzylpiperidin-4-yl)–N–(x-fluorophenyl)-butanamide. (H) 2-methyl-N-phenyl-N-[1–(1-phenylpropan-2-yl)piperidin-4-yl]propanamide. (I) N–(1-phenethylpiperidin-4-yl)–N-phenylbutyramide. (J) 1-cyclohexyl-4–(1,2-diphenylethyl)-piperazine. (K) N-phenyl-N–(1–(2–(thiophen-2-yl)ethyl)piperidin-4-yl)acetamide. (L) 4-chloro-N–(1-phenethylpiperidin-2-ylidene)benzenesulfonamide. (M) 4-chloro-N–(1–(4-nitrophenethyl)piperidin-2-ylidene)benzenesulfonamide. (9) Piperazines The substances listed in this paragraph consist of the following piperazines: (A) 1,4-dibenzylpiperazine. (B) 1–(4-bromo-2,5-dimethoxybenzyl)-piperazine. (C) 1–(4-fluorophenyl)-piperazine. (D) 1–(2-methoxyphenyl)-piperazine. (E) 1–(4-chlorophenyl)-piperazine. (F) 1–(4-methoxyphenyl)-piperazine. (G) 1–(3-methylbenzyl)piperazine. (H) 1-benzyl-4-methylpiperazine. (10) Tropane alkaloids The substances listed in this paragraph consist of the following tropane alkaloids: (A) 8-methyl-8-azabicyclo[3.2.1]octan-3-yl 4-fluorobenzoate. (B) methyl 3–(4-fluorophenyl)–8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate. . (b) Effective date The amendment made by subsection (a) takes effect on the date that is 30 days after the date of enactment of this Act.

tv_txt: I 114th CONGRESS 2d Session H. R. 3537 IN THE HOUSE OF REPRESENTATIVES AN ACT To amend the Controlled Substances Act to add certain synthetic substances to schedule I, and for other purposes.

1. Short title This Act may be cited as the Dangerous Synthetic Drug Control Act of 2016 . 2. Treatment of certain designer drugs as schedule I controlled substances (a) Cannabimimetic agents Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), is amended in subsection (d)(2)(B)— (1) in clause (xiv) by striking and at the end; (2) in clause (xv) by striking the period and inserting a semicolon; and (3) by adding at the end the following: (xvi) 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (JWH–251); (xvii) (1-butyl-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone (4′-methyl JWH–073); (xviii) 2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (JWH–302); (xix) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F–APICA); (xx) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F–PB–22); (xxi) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB–PINACA); (xxii) N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide (MN–24); (xxiii) (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone (THJ–2201); (xxiv) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADBICA); (xxv) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F–AMB); and (xxvi) methyl 2-(1-(cyclohexylmethyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (MA–CHMINACA). . (b) Synthetic opioids Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), is amended in subsection (a) by adding at the end the following: (43) Butyryl fentanyl. (44) beta-Hydroxythiofentanyl. (45) Acetyl fentanyl. . (c) Other drugs Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), is amended in subsection (c) by adding at the end the following: (29) 1-(naphthalen-1-yl)-2-(pyrrolidin-1-yl)pentan-1-one (α-naphyrone). (30) 1-(2,3-dihydrobenzofuran-5-yl)propan-2-amine (5–APDB). (31) 1-(2,3-dihydrobenzofuran-6-yl)propan-2-amine (6–APDB). (32) 6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-6-amine (MDAI). (33) 5-iodo-2,3-dihydro-1H-inden-2-amine (5–IAI). (34) 1-(4-bromofuro[2,3-f]benzofuran-8-yl)propan-2-amine (bromo-dragonfly). (35) 1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine (DOC). (36) 1-(4-ethoxy-2,5-dimethoxyphenyl)propan-2-amine (MEM). .

Passed the House of Representatives September 26, 2016. Karen L. Haas, Clerk.

tv_txt: IIB 114th CONGRESS 2d Session H. R. 3537 IN THE SENATE OF THE UNITED STATES September 27, 2016 Received; read twice and referred to the Committee on the Judiciary AN ACT To amend the Controlled Substances Act to add certain synthetic substances to schedule I, and for other purposes.

1. Short title This Act may be cited as the Dangerous Synthetic Drug Control Act of 2016 . 2. Treatment of certain designer drugs as schedule I controlled substances (a) Cannabimimetic agents Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), is amended in subsection (d)(2)(B)— (1) in clause (xiv) by striking and at the end; (2) in clause (xv) by striking the period and inserting a semicolon; and (3) by adding at the end the following: (xvi) 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (JWH–251); (xvii) (1-butyl-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone (4′-methyl JWH–073); (xviii) 2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (JWH–302); (xix) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F–APICA); (xx) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F–PB–22); (xxi) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB–PINACA); (xxii) N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide (MN–24); (xxiii) (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone (THJ–2201); (xxiv) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADBICA); (xxv) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F–AMB); and (xxvi) methyl 2-(1-(cyclohexylmethyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (MA–CHMINACA). . (b) Synthetic opioids Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), is amended in subsection (a) by adding at the end the following: (43) Butyryl fentanyl. (44) beta-Hydroxythiofentanyl. (45) Acetyl fentanyl. . (c) Other drugs Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), is amended in subsection (c) by adding at the end the following: (29) 1-(naphthalen-1-yl)-2-(pyrrolidin-1-yl)pentan-1-one (α-naphyrone). (30) 1-(2,3-dihydrobenzofuran-5-yl)propan-2-amine (5–APDB). (31) 1-(2,3-dihydrobenzofuran-6-yl)propan-2-amine (6–APDB). (32) 6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-6-amine (MDAI). (33) 5-iodo-2,3-dihydro-1H-inden-2-amine (5–IAI). (34) 1-(4-bromofuro[2,3-f]benzofuran-8-yl)propan-2-amine (bromo-dragonfly). (35) 1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine (DOC). (36) 1-(4-ethoxy-2,5-dimethoxyphenyl)propan-2-amine (MEM). .

Passed the House of Representatives September 26, 2016. Karen L. Haas, Clerk.

tv_txt: IB Union Calendar No. 615 114th CONGRESS 2d Session H. R. 3537 [Report No. 114–787, Part I] IN THE HOUSE OF REPRESENTATIVES September 17, 2015 Mr. Dent (for himself, Mr. Himes , Mr. Meehan , Mr. Dold , Mr. Tiberi , Mr. Costello of Pennsylvania , Mr. Hanna , Mr. Thompson of Pennsylvania , Mr. Rogers of Kentucky , Mr. Murphy of Pennsylvania , Mr. Barletta , Ms. Norton , Mr. Lance , Mrs. Comstock , Mr. Katko , Ms. Ros-Lehtinen , and Mr. Jolly ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on the Judiciary , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned September 26, 2016 Additional sponsors: Mr. Rodney Davis of Illinois , Mr. Cuellar , Mr. Guthrie , Mr. Thornberry , Mr. Bishop of Michigan , Mr. King of New York , Mr. Allen , Mr. Pierluisi , Ms. Kaptur , Mr. Peters , and Ms. Velázquez September 26, 2016 Reported from the Committee on Energy and Commerce with amendments Strike out all after the enacting clause and insert the part printed in italic September 26, 2016 The Committee on the Judiciary discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed For text of introduced bill, see copy of bill as introduced on September 17, 2015 A BILL To amend the Controlled Substances Act to clarify how controlled substance analogues are to be regulated, and for other purposes.

1. Short title This Act may be cited as the Dangerous Synthetic Drug Control Act of 2016 . 2. Treatment of certain designer drugs as schedule I controlled substances (a) Cannabimimetic agents Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), is amended in subsection (d)(2)(B)— (1) in clause (xiv) by striking and at the end; (2) in clause (xv) by striking the period and inserting a semicolon; and (3) by adding at the end the following: (xvi) 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (JWH–251); (xvii) (1-butyl-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone (4′-methyl JWH–073); (xviii) 2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (JWH–302); (xix) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F–APICA); (xx) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F–PB–22); (xxi) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB–PINACA); (xxii) N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide (MN–24); (xxiii) (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone (THJ–2201); (xxiv) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADBICA); (xxv) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F–AMB); and (xxvi) methyl 2-(1-(cyclohexylmethyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (MA–CHMINACA). . (b) Synthetic opioids Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), is amended in subsection (a) by adding at the end the following: (43) Butyryl fentanyl. (44) beta-Hydroxythiofentanyl. (45) Acetyl fentanyl. . (c) Other drugs Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), is amended in subsection (c) by adding at the end the following: (29) 1-(naphthalen-1-yl)-2-(pyrrolidin-1-yl)pentan-1-one (α-naphyrone). (30) 1-(2,3-dihydrobenzofuran-5-yl)propan-2-amine (5–APDB). (31) 1-(2,3-dihydrobenzofuran-6-yl)propan-2-amine (6–APDB). (32) 6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-6-amine (MDAI). (33) 5-iodo-2,3-dihydro-1H-inden-2-amine (5–IAI). (34) 1-(4-bromofuro[2,3-f]benzofuran-8-yl)propan-2-amine (bromo-dragonfly). (35) 1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine (DOC). (36) 1-(4-ethoxy-2,5-dimethoxyphenyl)propan-2-amine (MEM). .

Amend the title so as to read: A bill to amend the Controlled Substances Act to add certain synthetic substances to schedule I, and for other purposes. .

September 26, 2016 Reported from the Committee on Energy and Commerce with amendments September 26, 2016 The Committee on the Judiciary discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed